Title: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
Authors: Vermorken, J B ×
Peyrade, F
Krauss, J
Mesía, R
Remenar, E
Gauler, T C
Keilholz, U
Delord, J P
Schafhausen, P
Erfán, J
Brümmendorf, T H
Iglesias, L
Bethe, U
Hicking, C
Clement, Paul #
Issue Date: Mar-2014
Publisher: Kluwer Academic Publishers
Series Title: Annals of Oncology vol:25 issue:3 pages:682-8
Article number: 10.1093/annonc/mdu003
Abstract: Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science